Des-γ-Carboxy Prothrombin (DCP) as a Potential Autologous Growth Factor for the Development of Hepatocellular Carcinoma

被引:55
|
作者
Zhang, Yu-Sheng [1 ]
Chu, Jia-Hui [1 ]
Cui, Shu-Xiang [2 ]
Song, Zhi-Yu [1 ]
Qu, Xian-Jun [1 ]
机构
[1] Shandong Univ, Sch Pharmaceut Sci, Jinan, Peoples R China
[2] Capital Med Univ, Evaluat Ctr Food & Drug, Beijing, Peoples R China
关键词
Des-gamma-carboxy prothrombin (DCP); Hepatocellular carcinoma (HCC); Autologous growth factor; Paracrine factor; Stimulation; Angiogenesis; Signaling pathways; MONOCLONAL-ANTIBODIES MU-3; VITAMIN-K; ABNORMAL PROTHROMBIN; ALPHA-FETOPROTEIN; IMMUNOREACTIVE PROTHROMBIN; FIBROBLASTOID CONVERSION; PROGNOSTIC INDICATOR; ACID RESIDUES; LIVER-DISEASE; SERUM;
D O I
10.1159/000366308
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Des-gamma-carboxy prothrombin (DCP) is a prothrombin precursor produced in hepatocellular carcinoma (HCC). Because of deficiency of vitamin K or y-glutamyl carboxylase in HCC cells, the 10 glutamic acid (Glu) residues in prothrom bin precursor did not completely carboxylate to y-carboxylated glutamic acid (Gla) residues, leaving some Glu residues remained in N-terminal domain. These prothrombin precursors with Glu residues are called DCPs. DCP displays insufficient coagulation activity. Since Liebman reported an elevated plasma DCP in patients with HCC, DCP has been used in the diagnosis of HCC. Recently, its biological malignant potential has been specified to describe DCP as an autologous growth factor to stimulate HCC growth and a paracrine factor to integrate HCC with vascular endothelial cells. DCP was found to stimulate HCC growth through activation of the DCP-Met-JAK1-STAT3 signaling pathway. DCP might increase HCC invasion and metastasis through activation of matrix metalloproteinase (MMPs) and the ERK1/2 MAPK signaling pathway. DCP has also been found to play a crucial role in the formation of angiogenesis. DCP could increase the angiogenic factors released from HCC and vascular endothelial cells. These effects of DCP in angiogenesis might be related to activation of the DCP-KDR-PLC-gamma-MAPK signaling pathway. In this article, we summarized recent studies on DCP in biological roles related to cancer progression and angiogenesis in HCC. Copyright (C) 2014 S. Karger AG, Basel
引用
收藏
页码:903 / 915
页数:13
相关论文
共 50 条
  • [31] The Early Decline of α-Fetoprotein and Des-γ-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients
    Yamamoto, Shumpei
    Onishi, Hideki
    Takaki, Akinobu
    Oyama, Atsushi
    Adachi, Takuya
    Wada, Nozomu
    Sakata, Masahiro
    Yasunaka, Tetsuya
    Shiraha, Hidenori
    Okada, Hiroyuki
    GASTROINTESTINAL TUMORS, 2020, 7 (03) : 83 - 92
  • [32] Clinical Utility of Des-γ-Carboxy Prothrombin Kinetics as a Complement to Radiologic Response in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Park, Won-Hyeong
    Shim, Ju-Hyun
    Han, Seung-Bong
    Won, Hyung-Jin
    Shin, Yong-Moon
    Kim, Kang-Mo
    Lim, Young-Suk
    Lee, Han-Chu
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2012, 23 (07) : 927 - 936
  • [33] Measurement of serum levels of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity
    Okuda, H
    Nakanishi, T
    Takatsu, K
    Saito, A
    Hayashi, N
    Watanabe, K
    Magario, N
    Yokoo, T
    Naraki, T
    CANCER, 1999, 85 (04) : 812 - 818
  • [34] Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α-fetoprotein alone and those seropositive for des-γ-carboxy prothrombin alone
    Okuda, H
    Nakanishi, T
    Takatsu, K
    Saito, A
    Hayashi, N
    Yamamoto, M
    Takasaki, K
    Nakano, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (11) : 1290 - 1296
  • [35] Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis
    Yang, Ming
    Zhang, Xuejun
    Liu, Jinlong
    PLOS ONE, 2019, 14 (11):
  • [36] Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein
    Hamamura, K
    Shiratori, Y
    Shiina, S
    Imamura, M
    Obi, S
    Sato, S
    Yoshida, H
    Omata, M
    CANCER, 2000, 88 (07) : 1557 - 1564
  • [37] Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States
    Carr, Brian I.
    Kanke, Futoshi
    Wise, Margaret
    Satomura, Shinji
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (03) : 776 - 782
  • [38] Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
    Ueshima, Kazuomi
    Kudo, Masatoshi
    Takita, Masahiro
    Nagai, Tomoyuki
    Tatsumi, Chie
    Ueda, Taisuke
    Kitai, Satoshi
    Ishikawa, Emi
    Yada, Norihisa
    Inoue, Tatsuo
    Hagiwara, Satoru
    Minami, Yasunori
    Chung, Hobyung
    Sakurai, Toshiharu
    DIGESTIVE DISEASES, 2011, 29 (03) : 321 - 325
  • [39] Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin
    Inagaki, Yoshinori
    Tang, Wei
    Makuuchi, Masatoshi
    Hasegawa, Kiyoshi
    Sugawara, Yasuhiko
    Kokudo, Norihiro
    LIVER INTERNATIONAL, 2011, 31 (01) : 22 - 35
  • [40] Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma
    Kuzuya, Teiji
    Kawabe, Naoto
    Muto, Hisanori
    Wada, Yuryo
    Komura, Gakushi
    Nakano, Takuji
    Tanaka, Hiroyuki
    Nakaoka, Kazunori
    Ohno, Eizaburo
    Funasaka, Kohei
    Nagasaka, Mitsuo
    Miyahara, Ryoji
    Hirooka, Yoshiki
    CURRENT ONCOLOGY, 2024, 31 (08) : 4225 - 4240